linjc16/ctgov huggingface dataset:
Effect of Prophylactic Negative Pressure Versus Silver Impregnated Silicone Bandage on C-Section Infection Rates

Study Overview
=================
Brief Summary
-----------------
Effect of Prophylactic Negative Pressure versus Silver Impregnated Silicone Bandage on Cesarean Section Surgical Site Infection Rate

Detailed Description
-----------------
Comparison of effect of Prophylactic Negative Pressure versus Silver Impregnated Silicone Bandage on Cesarean Section Surgical Site Infection Rate as compared to wound vacuum in high risk women and traditional border dressing in low risk women in adult women having uncomplicated cesarean section.

Official Title
-----------------
Effect of Prophylactic Negative Pressure Versus Silver Impregnated Silicone Bandage on Cesarean Section Surgical Site Infection Rate

Conditions
-----------------
D001458, D011247

Intervention / Treatment
-----------------
* Device: silver impregnated dressing


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: adult women, pregnant Exclusion Criteria: <18 years old surgery complicated by non-routine surgeries (Such as appendectomy)

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 55 Years

Sexes Eligible for Study
-----------------
Female

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| low risk, silver impregnated<br>low risk, silver impregnated | Device: silver impregnated dressing<br>* comparison of Mepilex versus our standard techniques<br>* Other names: Wound vacuum;|
| low risk, border bandage<br>low risk, border bandage | |
| high-risk, silver impregnated<br>high-risk, silver impregnated | Device: silver impregnated dressing<br>* comparison of Mepilex versus our standard techniques<br>* Other names: Wound vacuum;|
| high-risk, wound vacuum<br>high-risk, wound vacuum | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Infection Rate | rate of post operative infection | 30 days from surgery | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
infection, bandage, cesarean section
Inflammatory Response to Anti Inflammatory Therapy in Children With Sleep Disordered Breathing

Study Overview
=================
Brief Summary
-----------------
This study will assess in a double blind placebo controlled fashion the effects of a 12 week course of oral montelukast/placebo on polysomnographic and radiological findings and will characterize the systemic (serum,urine) and local (upper airway collected biological samples) inflammatory response in children (2-10 years of age) with sleep disordered breathing, fittingthe inclusion and exclusion criteria.

Official Title
-----------------
Inflammatory Response to Anti Inflammatory Therapy in Children With Sleep Disordered Breathing

Conditions
-----------------
Sleep Disordered Breathing

Intervention / Treatment
-----------------
* Drug: Montelukast


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria:2-10 years old 1<AHI<8 measured in an overnight PSG - Exclusion Criteria: Asthma Previous use or allergy to montelukast Use of antibiotics in the previous 3 weeks Use of corticosteroids in the previous 3 months Craniofacial dysmorphism Genetic or metabolic defined illnesses Adenotonsillectomy or adenoidectomy in the past -

Ages Eligible for Study
-----------------
Minimum Age: 2 Years
Maximum Age: 10 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Montelukast|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
Impact MRSA -PCR on Patient Management

Study Overview
=================
Brief Summary
-----------------
Staphylococcus aureus represents one of the most met germs, with Escherichia coli, during bacteremia. Microbiologist distinguish at aureus S. two profiles of resistance in beta-lactamines: S. aureus sensitive to the methicillin ( SASM) and the S. aureus resistant to the methicillin ( SARM). With the implementation of the MALDI-TOF, it is now possible to identify the origin responsible of the bacteremia the day of the positivity of the hemoculture ( J0) and to set up a treatment with adapted antibiotic, which, in the case of a sepsis to aureus S., is the vancomycine. Ye it was demonstrated, that the use of the vancomycine on the SASM increased the average duration of stay and a more important rate of relapse. The PCR SARM was organized in the GHPSJ in 2014. It allows from the day of the positivity of the hemoculture ( J0), to determine the phenotype of resistance of S. aureus.

Official Title
-----------------
Impact MRSA -PCR on Patient Management

Conditions
-----------------
MRSA Bacteremia

Intervention / Treatment
-----------------
* Diagnostic Test: Polymerase Chain Reaction of Methicillin Resistant Staphyloccus Aureus


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Hemoculture positive to Staphylococcus Aureus Methicillin Sensitive Exclusion Criteria: Positive test to Staphylococcus Aureus Methicillin Sensitive but not hospitalized.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Diagnostic Test: Polymerase Chain Reaction of Methicillin Resistant Staphyloccus Aureus|Polymerase Chain Reaction of Methicillin Resistant Staphyloccus Aureus|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Adaptation duration of antibiotherapy |  | 24 hours | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Mortality |  | Day 30 | 
| average duration of hospitalization |  | day 30 |
Pulmonary Hypertension in Patients Attending Sohag University Hospital: A Focus on The Etiology

Study Overview
=================
Brief Summary
-----------------
Assessment of pulmonary hypertension in patients attending Sohag university hospital ( in out patient clinic or in patient) focusing on the etiology of pulmonary hypertension

Official Title
-----------------
Pulmonary Hypertension in Patients Attending Sohag University Hospital: A Focus on The Etiology

Conditions
-----------------
Patients With Pulmonary Hypertension

Intervention / Treatment
-----------------
* Other: echocardiography


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: patients who are 18 years old or more patients with pulmonary hypertension diagnosed with echocardiography Exclusion Criteria: patient who are less than 18 years old

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| patients with pulmonary hypertension<br>patients who are more than 18 years old , diagnosed with pulmonary hypertension by echocardiography | Other: echocardiography<br>* All the patients will be subjected to thorough medical history and clinical examination and the results of the previous investigations will be collected aiming for reaching the diagnosis of the etiology of pulmonary hypertension. ct pulmonary angiography and then right heart catheterization will be done in case of undiagnosed etiology.<br>* Other names: right heart catheterization;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Detection of the causes of pulmonary hypertension in patients attending Sohag university hospital | We will diagnose the cause of pulmonary hypertension in each participant. This will be done by following the diagnostic algorithm of European Society of Cardiology/ European Respiratory Society (ESC/ERS) 2015 guidelines (e.g. we will exclude that pulmonary hypertension is secondary to pulmonary disease by performing adequate assessment of the patient medical history and clinical examination, performing chest x-ray and or high resolution CT chest, spirometry...), so we will know the pattern of pulmonary hypertension etiology in patients attending of Sohag university hospital | one year |
Gemcitabine and Capecitabine in Patients With Advanced Pancreatic Cancer

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to test the effectiveness and safety of the drug combination of gemcitabine and capecitabine (Xeloda) in patients with advanced pancreatic cancer.

Official Title
-----------------
Phase I Trial of Gemcitabine and Capecitabine (Xeloda) in Patients With Advanced Pancreatic Carcinoma

Conditions
-----------------
Pancreatic Cancer

Intervention / Treatment
-----------------
* Drug: Capecitabine (Xeloda)
* Drug: Gemcitabine


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Metastatic or unresectable pancreatic cancer No prior chemotherapy except radiation-sensitizing doses of 5-FU No radiotherapy less than 4 weeks prior to the start of the study Exclusion Criteria: Prior unanticipated severe reaction to fluoropyrimidine therapy or known hypersensitivity to 5-FU Moderate to severe renal impairment Uncontrolled diabetes Inability to swallow tablets

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Capecitabine (Xeloda)|650 mg/m2 po bid Days 1-14 750 mg/m2 po bid Days 1-14 850 mg/m2 po bid Days 1-14 950 mg/m2 po bid Days 1-14|
|Drug: Gemcitabine|750 mg/m2 IV Days 1 & 8 q 21 days|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| MTD and DLT for the combination therapy of gemcitabine and capecitabine |  | January 2010 | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Tumor Response |  | January 2010 |
Nutritional Status and Quality of Life in Older Adults

Study Overview
=================
Brief Summary
-----------------
The aim of this study is to determine the nutritional status, and factors affecting malnutrition in older people staying in hospitals. Objectives: To recruit a sample of older people in hospital To collect information on nutritional status, satisfaction with food-related life and experience with access to food in hospital. To assess the staffing attitudes to nutritional care of the older adult To undertake an audit of therapeutic ('special') diets served in hospitals, with respect to their nutritional adequacy and wastage To investigate predictors and correlates of malnutrition within the hospital setting and compare these relationships with those previously identified in care homes and the community. To make recommendations for practice to improve the nutritional status of hospitalised older adults.

Official Title
-----------------
Nutritional Status and Quality of Life in Older Hospitalised Adults

Conditions
-----------------
Malnutrition

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Aged ≥ 75 years old Male or female Duration of stay is more than 24hrs Able to eat normally Able to read and write English Able to be weighed standing or sitting OR accurate weight available since admission Exclusion Criteria: Age below 75 years old Newly admitted patient (less than 24hrs) Certain medical conditions likely to affect digestion/ absorption of nutrients (researchers will assess) Unable to provide informed written consent Patients on gastric surgical wards or suffering from gastritis Patients currently taking laxatives Unable to be weighed and no measured weight available (self report weight is not adequate)

Ages Eligible for Study
-----------------
Minimum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Nutritional status | Using MNA | baseline | 
| Satisfaction with food related quality of life |  | baseline | 
| Dietary intake | 3 x 24hr recalls | baseline | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Food Access in Hospital |  | baseline | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
elderly care, quality of life, hospital, malnutrition
NYU/Bellevue WTC Health Impacts Research Registry

Study Overview
=================
Brief Summary
-----------------
The American Red Cross has funded a multidisciplinary, comprehensive evaluation and treatment program for target individuals with suspected World Trade Center (WTC)-related health problems. The populations served consist predominantly of a) local residents who were impacted by the disperion of the WTC dusts and fumes, b) individuals involved in cleaning and debris removal of local commercial spaces, and c) responders to the WTC collapse. These populations are recruited from past and ongoing programs that we have developed as well as from ongoing collaborations with community organizations that include: the Beyond Ground Zero Network, 9/11 Environmental Action committee, and the WTC Residents Coalition. In addition, there is collaboration with the Charles B. Wang Community Health Center and the centers involved in the ongoing WTC Workers and Volunteer Medical Screening and Monitoring Program. We would now like to access the data from this treatment program to create a NYU/Bellevue WTC Health Impacts Research Registry to increase knowledge about the health effects of exposure to World Trade Center dust.

Official Title
-----------------
NYU/Bellevue Red Cross WTC Health Impacts Research Registry

Conditions
-----------------
Exposure to World Trade Center Dust

Participation Criteria
=================
Eligibility Criteria
-----------------
Target populations who will participate in the Bellevue Hospital Red Cross WTC Health Impacts Program will include: residents (children and adults) of Lower Manhattan communities at the time of the attacks, who remained or returned to their homes soon after the attacks individuals involved in debris removal in surrounding commercial and residential buildings, individuals involved in rescue, recovery and debris removal who have been previously screened through the World Trade Center Worker and Volunteer Medical Screening Program and are in need of continued treatment.
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Respiratory Status |  | June 2020 | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Mental Health Status |  | June 2020 | 
| General Health Status |  | June 2020 | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
World Trade Center dust
Survey of Non-Variceal Upper Gastro Intestinal Bleeding in Vietnamese Patients

Study Overview
=================
Brief Summary
-----------------
The main aim of the study is to describes the outcomes of patients with Upper Gastrointestinal Bleed (UGIB) in a real-life setting. Additionally analyse assessed predictors of outcome, including the impact of hemostatic endoscopic and pharmacologic therapies.

Detailed Description
-----------------
MSD

Official Title
-----------------
Survey of Non-Variceal Upper Gastro Intestinal Bleeding in Vietnamese Patients

Conditions
-----------------
Re-bleeding in NVUGIB

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Adult patients (>=18yrs) admitted to the hospital, or inpatients admitted for another reason, presenting with overt non-variceal upper GI bleed manifesting as hematemesis/coffee ground vomiting, melena, hematochezia... Evidence that an upper GI endoscopy was performed Exclusion Criteria: GI bleeding not from NVUGIB

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| 1<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Rebleeding (within 7 days from the Non-Variceal Upper Gastro Intestinal Bleeding (NVUGIB) episode) |  | 7 days | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Surgery due to re-bleeding |  | 7 days | 
| Mortality due to bleeding |  | 7 days | 
| Rebleeding in high risk peptic ulcer patients |  | 7 days | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Re-bleeding, NVUGIB
Effect of Use of Straw on Tolerability and Quality of Split Dose 4l-PEG Preparation

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to determine whether patients drinking their bowel preparation solution with a straw will have improved tolerability for ingestion of their bowel preparation solution and achieve a higher bowel preparation quality score than patients drinking their bowel preparation solution without a straw.

Official Title
-----------------
Effect of Use of Straw on Tolerability and Quality of Split Dose 4l-PEG Preparation

Conditions
-----------------
Colon Cancer

Intervention / Treatment
-----------------
* Other: Straw


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients over 18 y/o scheduled for elective outpatient colonoscopy Exclusion Criteria: History of colonic surgery, Contra-indication for preparation (PEG solution), History of inflammatory bowel disease

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| No Intervention: Routine<br>Subjects will ingest the bowel preparation from a cup | |
| Experimental: Straw<br>Subjects will ingest the bowel preparation with a straw | Other: Straw<br>* Bowel preparation ingestion with a straw<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Bowel preparation quality | Bowel preparation quality will be measured using a validated scoring system (Boston Bowel Preparation Score) for bowel preparation | 1 day | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Tolerability will be measured by subjective survey including a 5-point scale and a visual analog scale filled by the subjects the day of the colonoscopy |  | 1 day | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
bowel preparation
Coronavirus: Ventilator Outcomes Using Artificial Intelligence Chest Radiographs & Other Evidence-based Co-variates

Study Overview
=================
Brief Summary
-----------------
We will determine ventilator outcomes to Coronavirus Infectious Disease 2019 (COVID-19) using artificial Intelligence with inputs of chest radiographs and other evidence-based co-variates.

Detailed Description
-----------------
The chest radiograph (chest x-ray) has emerged as the United Kingdom's National Health Service (NHS) frontline diagnostic imaging test for COVID-19, in conjunction with clinical history and key blood markers: C-reactive protein (CRP) and lymphopenia. Typically, every suspected COVID-19 patient presenting to the emergency department is undergoing blood tests and a chest radiograph. Therefore, it has become critical for radiologists to review and hot report the chest x-ray urgently. Primary Objective: Use chest radiographs and clinical data to determine whether patient can survive with a ventilator

Official Title
-----------------
Coronavirus Infectious Disease 2019: Ventilator Outcomes Using Artificial Intelligence, Chest Radiographs and Other Evidence-based Co-variates (COVID VOICE)

Conditions
-----------------
Covid19, Pneumonia

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Admitted to intensive care unit (ITU) or equivalent COVID-19 polymerase chain reaction (PCR) positive Exclusion Criteria: No imaging prior to ITU admission

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| wave 1<br> | |
| wave 2<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Sensitivity and specificity of a convolutional neural network to predict survival outcome | Defined by sensitivity, specificity, positive and negative predictive values | 1 month |